Integral Diagnostics Ltd

IDX: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|d#T%<PBLOCK|BxLOCK|dSxptMQ

Integral Diagnostics Earnings: Shares Undervalued With Margins Expanding to Plan

Integral's interim 2026 underlying revenue grew 7% while operating EBITDA margin rose a strong 130 basis points to 21% on a pro forma basis. They kept full-year operating EBITDA margin guidance of 21%, implying a slight second-half uplift on normal sales seasonality and as cost savings annualize.

Sponsor Center